All Industries

Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate

Benzinga

By James Blacker, Benzinga Mainz Biomed NV (NASDAQ: MYNZ), a company that specializes in the early detection of cancer, recently shared encouraging topline results from a clinical study designed to test the next-generation version of its colorectal cancer screening tool, ColoAlert®. The company recently unveiled compelling findings from its most expansive group to date at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, as well as virtually. The comprehensive examination consisted of 690 participants from 30 reputable gastroenterology facilities in Europe and the United States, and introduced previously unexplored and unreported specimens. The results underscored the effectiveness of Mainz Biomed's multimodal screening test, marking significant advancements in colorectal cancer detection. Notable figures include a sensitivity of 92.3% for colorectal cancer, a specificity of 90.1%, a sensitivity rate of 82.2% for advanced precancerous lesions, and an impressive high-grade dysplasia detection rate of 95.8%. With the success of this study, Mainz Biomed now plans to move forward with a major clinical trial in the U.S., which will involve up to 15,000 participants. If this next trial produces positive results, the company says its next-generation tool has the potential to disrupt the at-home colorectal cancer screening market by becoming a new gold standard. “The new data read-out demonstrates that our next generation product candidate for early-stage CRC detection utilizing mRNA biomarkers, a FIT test and a proprietary AI algorithm has consistently delivered high sensitivity and specificity for both advanced adenomas and colorectal cancer,” said Guido Baechler, CEO of Mainz Biomed, “These results represent a critical milestone on our path to launching our FDA PMA pivotal study ReconAAsense, which is planned to recruit up to 15,000 patients.” Why Early Detection Matters According to the American Cancer Society’s latest publication, the incidence of colorectal cancer has increased alarmingly since the mid-1990s, continuing to rise between 1% and 2% each year in people under the age of 55. Since the mid-2000s, the mortality rate among young people has increased at a similar rate. Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer-related deaths worldwide. However, it is also the most preventable, with early detection leading to survival rates above 90 %. About Mainz Biomed Founded in Germany, Mainz Biomed is becoming a leading global provider of easy-to-use diagnostic solutions for patients and healthcare providers everywhere. The company develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States and the rest of the world, and develops innovative products to quickly and reliably identify the early onset of several leading deadly conditions – such as pancreatic cancer and colorectal cancer. The company reports that its CE-IVD-cleared flagship product, ColoAlert, is the first DNA-based screening test for colorectal cancer in Europe, and that it is developing proprietary genetic testing methods for pancreatic cancer. For 2023, the company earned revenues of $895,479, which compared to revenues of $529,877 in 2022. What Sets ColoAlert Apart In a market with established players such as Cologuard from Exact Sciences Corporation (NASDAQ: EXAS), ColoAlert stands out as an innovative product that addresses the need for a convenient and user-friendly test. Mainz Biomed claims that ColoAlert is not only more effective than traditional blood tests at detecting precancerous polyps early but also detects more cases of colorectal cancer than other stool tests. As Mainz Biomed plans its upcoming major trial in the U.S., the company could be one to watch as a force in the fight against cancer. More information about the company can be found at mainzbiomed.com. Featured photo by Gerd Altmann on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

June 05, 2024 08:30 AM Eastern Daylight Time

Image

OncoCyte's Innovative Approach: Potential in Precision Diagnostics

RazorPitch OCX

Chronic conditions such as organ transplant rejection and cancer represent significant challenges in modern healthcare, demanding precise diagnostic tools for effective management and treatment. For organ transplant patients, the risk of graft rejection remains a persistent threat, necessitating continuous monitoring to ensure long-term success. Similarly, the complexity of cancer requires advanced diagnostics to tailor treatments to individual patients, optimizing therapeutic efficacy while minimizing adverse effects. Amidst these challenges, OncoCyte Corporation (NASDAQ: OCX ) has emerged as an innovative player in the precision diagnostics market. The company's tests enhance clinical outcomes for patients undergoing organ transplants and cancer treatments. With recent strategic partnerships and regulatory advancements, OncoCyte has spearheaded transformative advancements in the field. OCX’s product portfolio includes VitaGraft, a clinical blood-based test for monitoring solid organ transplants, and GraftAssure, a research-use-only test for the same purpose. Additionally, DetermaIO and DetermaCNI are designed for oncology applications, predicting responses to immunotherapies and monitoring therapeutic efficacy, respectively. Partnerships In April 2024, OCX partnered with Bio-Rad Laboratories (NYSE: BIO) to commercialize the GraftAssure assay. This agreement leverages Bio-Rad's extensive reach and expertise in the life sciences sector, facilitating the co-marketing of GraftAssure in the U.S. and Germany. Bio-Rad holds exclusive global distribution rights outside these regions. This collaboration is pivotal for scaling OncoCyte's operations and meeting the growing demand for transplant diagnostics. The partnership also includes an option for Bio-Rad to acquire IVD commercial rights upon FDA clearance, subject to specific milestones. This option comes with a second equity investment into OncoCyte, reflecting Bio-Rad's confidence in the product's market potential. Riggs noted, "The QX600 ddPCR platform, along with their expertise in the life science market, makes Bio-Rad a natural partner for our transplant technology." Financial Performance OncoCyte's Q1 2024 financial results indicate a strategic focus on commercialization and cost-efficiency. The company reported gross proceeds of $15.8 million from an equity private placement, including a significant investment from Bio-Rad. This funding is crucial for advancing OncoCyte's product pipeline and expanding its market presence. Operational efficiency is evident, with OncoCyte reducing its cash burn to $3.9 million, reflecting a capital-efficient business model. The collaboration with Bio-Rad and the anticipated commercial launch of GraftAssure RUO test kits in Asia, the U.S., and the EU are expected to drive revenue growth and broaden the company's market reach. Riggs remarked, "The collaboration with Bio-Rad is pivotal for the upcoming launch of our GraftAssure RUO transplant rejection diagnostic test kit and central to our mission of developing accessible point-of-care diagnostics and continuous innovation in transplant rejection monitoring." Publication in New England Journal of Medicine OCX announced a significant milestone on May 30, 2024, with the publication of promising data on VitaGraft Kidney in the New England Journal of Medicine. This phase 2 study highlights VitaGraft Kidney’s potential to revolutionize kidney transplant care by accurately monitoring graft health through measuring donor-derived cell-free DNA (dd-cfDNA). For investors, this development signals substantial market potential. VitaGraft Kidney's ability to monitor therapeutic efficacy and detect disease recurrence opens new revenue streams. This test could become a standard in post-transplant care, driving repeated testing and long-term revenue. VitaGraft Kidney addresses a critical unmet need. Up to 20.2% of kidney transplant patients develop antibody-mediated rejection (AMR) within 10 years, with no FDA-approved drugs currently available for AMR management. The combination of VitaGraft testing and felzartamab therapy offers a promising solution, potentially improving patient outcomes and healthcare efficiency. OCX CEO Josh Riggs emphasized the breakthrough nature of this study, stating, “This positions VitaGraft Kidney as a crucial tool in managing transplant health. Our recent partnership with Bio-Rad expands our capacity to deliver these innovative solutions globally.” Riggs highlighted the test’s competitive edge in detecting AMR up to 10 months earlier than current protocols, enhancing patient care, and strengthening OncoCyte’s market position. The findings will be presented at the 2024 American Transplant Congress on June 3, 2024. This presentation is expected to further validate VitaGraft Kidney’s clinical value and could act as a catalyst for broader market adoption. OncoCyte’s latest publication not only validates VitaGraft Kidney’s clinical potential but also strengthens the company’s market position. As OCX continues to innovate and expand its market reach, investors can anticipate significant growth opportunities in the precision diagnostics sector. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by PCG Advisory Inc. to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Inc Mark McKelvie +1 585-301-7700 Mark@razorpitch.com Company Website http://razorpitch.com

June 05, 2024 07:00 AM Eastern Daylight Time

Clarified Precision Medicine and xCures Form Strategic Partnership to Transform Patient Outcomes Through Precision Oncology

Clarified Precision Medicine

Clarified Precision Medicine, the only company that provides oncologists with prioritized therapy options via a combination of expert medical provider review and underlying artificial intelligence (AI) computational algorithms, and xCures, a healthcare technology company that delivers real-time clinical data to power precision medicine support, today announced a strategic partnership to dramatically advance the field of precision oncology. The two companies will come together to enhance cancer-care delivery and personalized patient treatment recommendations through precision medicine and data-driven analysis. The goal of the alliance is to better identify and understand current gaps in providing precision medicine and ultimately improve patient outcomes. Oncology faces an immediate need to improve access to precision medicine. In the United States, there are 18 million patients with a history of cancer and 1.9 million new cancer diagnoses each year. Patients who receive precision therapies have survival rates that are three times greater than those who do not. However, 75 percent of doctors say they need help interpreting the genomic tests that make precision medicine possible — which, in turn, leads to more effective utilization of these powerful 21st-century tools. To that end, Clarified and xCures will collaborate on patient-level data analytics and work together to improve provider support, education, and communication. The two organizations will develop learning systems focused on innovative solutions in precision oncology, such as predictive analytics and treatment optimization. Clarified will contribute its specialized treatment recommendation system, which combines insights from experienced medical professionals with support from its AI-driven treatment algorithm. The company’s team of expert medical reviewers will provide clinical oversight. xCures will provide its AI-driven technology platform, which excels at extracting the critical information needed for care among the complex cancer patient data and enhancing access to medical records. “This partnership unites two of the most innovative leaders in the field of precision oncology,” said Clarified Precision Medicine CEO Rajni Natesan, MD, MBA. “Clarified is the leading expert in closing gaps at the last mile of precision oncology, with an AI platform and the greatest understanding of physician needs and individual patient outcomes. xCures is a leader in data and technology that transforms clinical efficiency and patient care. This powerful alliance enables us to overcome obstacles in cancer care that can only be addressed by an advanced, data-driven understanding of oncology at the patient level.” "We are excited to partner with Clarified Precision Medicine to harness the power of real-time clinical data and advanced analytics,” said xCures CEO Mika Newton. “This collaboration will enable us to deliver highly personalized and effective treatment recommendations, ultimately improving patient outcomes in precision oncology. By combining our strengths, we can address the critical need for better access to precision medicine and support oncologists in making data-driven decisions that enhance patient care." In addition to improving the utilization of precision medicine, the alliance will have significant capabilities in data collection and analytics to drive precision oncology research. The technology integration between Clarified and xCures will facilitate retrospective and prospective data analysis to improve treatment strategies and patient care outcomes. About Clarified Precision Medicine Clarified Precision Medicine is the first scalable molecular tumor board with a combination of ML-based platform plus medical group, offering expert clinical somatic and pharmacogenomics consultations through its ClarifiedSelect™ and OncoGuardian™ solutions. Clarified accelerates the delivery of guidelines-based genomic insights to patients and providers by bringing together nationally recognized experts in medical oncology, oncology pharmacy, data integration, and molecular pathology who have over 100 years of collective experience in the application of precision oncology. For more information, visit clarifiedprecisionmedicine.com About xCures Inc. Launched in 2018, xCures Inc. operates an AI-assisted platform that automatically retrieves and aggregates medical records from any US care site. Data is extracted and structured within 15 minutes, to offer a sophisticated view of a patient’s fully longitudinal health journey that encompasses everything from genomics to social determinants of health. Through a variety of tools and data products, xCures provides clinically actionable, real-time insights that facilitate clinical research and care for patients, providers, and partners. For more information, contact info@xcures.com, or visit www.xcures.com Contact Details For Clarified Precision Medicine info@clarifiedmedicine.com Company Website https://clarifiedprecisionmedicine.com/

June 04, 2024 03:00 PM Eastern Daylight Time

VISIONARY DIRECTOR JONATHAN BAKER ANNOUNCES FINAL FILM “ICON” AND SETS PRODUCTION FOR 2025

FATE

Los Angeles, CA (May 28, 2024) - Baker Entertainment Group, a film development and production company rooted in the tradition of classic Hollywood romance by visionary filmmaker Jonathan Baker, announced today it has wrapped production on “Fate” and is looking ahead to its next and final film. Baker’s next project “ICON” will be his final act as he sets sail on his directorial career in Hollywood. ”ICON” is about a soul that moves through a hundred years until it reaches its destiny as a rock star, using one family’s saga through immigration and musical history as its backdrop. “ICON” will head into production in 2025. "I've waited my entire life to share this story," said Jonathan Baker. "This narrative of ICON is crucial to America, highlighting the significance of immigration and how it shaped our nation. Our past is integral to our identity. A film like ICON is truly unique; it blends a historical perspective with a musical lens like never before." Baker envisions a star-studded ensemble cast coming together to create what he calls “a musical masterpiece” for “ICON”. Production on Baker’s last film “Fate” has wrapped, featuring an all star cast that includes Academy Award-winning actor Faye Dunaway (“Bonnie & Clyde”, “Chinatown”), Academy Award-nominee Harvey Keitel (“Bugsy”, “Taxi Driver”), Actor, Director, Writer, Andrew McCarthy (“The Blacklist,” “Orange is the New Black”, “Brats”), Brandon Routh (“Superman Returns”), Mena Suvari (“Grace and Grit”), Cheech Marin (“From Dusk Till Dawn”), and Janet Montgomery (“Black Swan”, “Black Mirror”). “The magic of the film is that everyone is not what they appear to be”, said Academy Award-winner Faye Dunaway. Jonathan Baker spent two years crafting the cast of “Fate” by hiring against type for each role. “Fate” and “ICON” are both co-written by Micheal Buhlman and Jonathan Baker. “Fate” is currently looking for a domestic distributor who believes in theatrical releases. Highland Film Group is handling international sales which kicked off at this year's Cannes Film Festival. For more information, please visit https://www.bakerentertainmentgroup.com/. ### Contact Details Jive PR + Digital Jordan Parlee jordan@jiveprdigital.com Company Website https://www.bakerentertainmentgroup.com

June 04, 2024 02:31 PM Eastern Daylight Time

HTX Issues Security Alert Regarding Exchange Accounts Amid Rising Cyber Treats

HTX

Singapore / June 3, 2024 – In light of the increasing sophistication of recent cyberattacks targeting cryptocurrency exchange accounts, HTX, the crypto exchange giant, reportedly issued an urgent security alert to its worldwide users to enhance their security vigilance for safeguarding assets. Recent Cyberattacks and Analysis Case 1: A user's Chrome browser was infiltrated via the malicious "Aggr" plugin, resulting in the hijacking of browser cookies. Attackers exploited these cookies to access the user's account of a certain exchange without a login password and 2FA code and transfer out $1 million assets by wash trading. Case 2: Another user fell victim to a sophisticated attack where attackers purchased their personal information on Telegram. The attackers manipulated the user's exchange account through email login and the forgot password option. Subsequently, they applied to change account settings, such as phone number, email address, and even Google Authenticator with AI-generated videos. This breach culminated in the theft of over $2 million assets after 24 hours of changing the account password. These cases underscore the evolvement of cyber threats, particularly as AI technology is increasingly leveraged by malicious actors. It would be the best if users adopt robust security measures to protect their personal information and assets. For those holding substantial investments, it is critical to implement measures for stringent privacy and isolation, such as disabling third-party plugins and regularly logging out of accounts. HTX’s Commitment to User Asset Security: Timely Upgrade of Security System As a world-leading cryptocurrency exchange, HTX is unwavering in its priority for user asset security. The exchange's security team continuously enhances its security management including security reserves and real-time security upgrades to counteract emerging threats. HTX advises users to adhere to the following security practices: 1. Phone Security: When accessing HTX on smartphones, ensure your device security by avoiding the installation of untrusted third-party apps. Only download the HTX app from official app stores and authorized channels. 2. PC Security: For login via PC, ensure your device is protected with robust antivirus software. Avoid installing untrusted third-party applications and browser extensions. Moreover, HTX maintains a reserve ratio exceeding 100%, assuring users that their assets are always fully withdrawable. The exchange provides monthly disclosures of reserve ratios and open-source verification tools for Merkle tree data, wallet address ownership, and on-chain assets. Looking ahead, HTX is poised to employ even higher financial standards to ensure the long-term security of user assets. About HTX Founded in 2013, HTX has evolved over a decade from a simple cryptocurrency exchange to a comprehensive blockchain business ecosystem. This expansion covers a wide range of services including digital asset trading, financial derivatives, wallets, research, investments, incubation, and more. As a world-leading portal to Web 3.0, HTX is committed to a growth strategy focused on global expansion, ecological prosperity, wealth effect, and safety and compliance. This approach enables us to offer comprehensive, safe, and reliable services and value to virtual currency enthusiasts around the world, reinforcing our position as a global gateway to Web3. Contact Details Michael Wang glo-media@htx-inc.com Company Website https://www.htx.com About HTX Founded in 2013, HTX has evolved over a decade from a simple cryptocurrency exchange to a comprehensive blockchain business ecosystem. This expansion covers a wide range of services including digital asset trading, financial derivatives, wallets, research, investments, incubation, and more. As a world-leading portal to Web 3.0, HTX is committed to a growth strategy focused on global expansion, ecological prosperity, wealth effect, and safety and compliance. This approach enables us to offer comprehensive, safe, and reliable services and value to virtual currency enthusiasts around the world, reinforcing our position as a global gateway to Web3. Contact Details Michael Wang glo-media@htx-inc.com Company Website https://www.htx.com/

June 04, 2024 02:11 PM Eastern Daylight Time

Mediavine Builds Out C-Suite with New Executive Promotions

Kite Hill PR

Mediavine, the largest exclusive full-service ad management firm in the U.S., is building out its C-Suite with key executive promotions. Amanda Martin is taking the newly created role of Chief Revenue Officer (CRO), while Jamie Lieberman expands her role from Chief Legal Officer to Chief Legal Officer & Chief Operations Officer (CLO/COO). These strategic additions to the leadership team enable Mediavine to proactively find solutions within the media industry while continuing to propel Mediavine’s business growth by bringing the highest value to the buy and sell sides including agencies, brands and publishers. Martin joined Mediavine over a year ago as SVP of Monetization and Business Strategy to optimize growing relationships across the buy and sell sides and has been a key representative for Mediavine in the industry. Martin will lead all revenue related activity including Sales, AdTech, Ad Operations, Partnerships & Commercial Data Strategy, while overseeing Mediavine’s growing DSP and SSP relationships. Martin will also be responsible for Mediavine’s marketing efforts which include a strategic move to tie marketing initiatives more closely to revenue. Previously, Martin served as SVP of Corporate Development and Strategic Partnerships at digital agency Goodway Group. “I have always been a firm believer that collaboration between the buy and sell sides is what yields the best results for both. This has been how I approached my role at Mediavine, helping our extensive publishing community navigate big industry changes and expand Mediavine beyond supply to highlight the audience strengths of mid to long tail publishers,” said Amanda Martin. “In my new role as CRO, I remain focused on the connection between demand generated from the buy side to the benefit of the publisher and sell side.” The strategic decision to combine the legal and operations roles at Mediavine is a reflection of the industry's changing landscape and Lieberman's experience as Mediavine's General Counsel, during which she operationalized numerous aspects of the business. This experience has allowed her to integrate processes to create a more sophisticated data-driven organization. In her new role, she continues to influence strategic direction on policies and procedures, intellectual property, contract negotiations and compliance, while also taking on Operations, including Project Management, InfoSec, IT, and Business Intelligence. "Privacy and data are two important pillars to our organization, and I am delighted to have the opportunity to oversee the legal and operations teams at Mediavine to ensure we are leading the industry through our approach,” said Jamie Lieberman. "I look forward to working closely with our team to ensure that we continue to navigate the legal and operational challenges of the digital media industry successfully." “We are excited to build out our C-Suite with the introduction of these two important roles. Amanda and Jamie have proven themselves to be highly strategic and innovative leaders who are helping to evolve our company in a way that sets us up for continued success. By streamlining operations, legal, marketing and sales, we become more agile, effective and ultimately a stronger partner to our publishers as well as brand and agency partners,” said Eric Hochberger, Mediavine Co-Founder and CEO. “I am also personally proud to expand the leadership team with two women who are strong believers in supporting and promoting other women in AdTech, a value that Mediavine and I share and will continue to champion.” About Mediavine Mediavine is the largest exclusive independent full-service ad management company, representing and monetizing approximately 11,000 publisher partner websites with 1.6 billion monthly pageviews in addition to its owned and operated properties. Mediavine proudly ranks as a Comscore top two lifestyle property with 150+ million unique monthly visitors and 17 billion monthly ad impressions. Mediavine is a Google Certified Publishing Partner - Premier, Great Place to Work®, I nc. 2022 Best Workplace, Fortune 2022 Best Medium Workplace, Ad Age 2022 Best Place to Work, and 2023 Inc. 5000. To learn more about Mediavine, visit www.mediavine.com or follow us on Twitter, Facebook, LinkedIn and Instagram. Contact Details Kite Hill PR Geanna Diaz mediavine@kitehillpr.com

June 04, 2024 11:00 AM Eastern Daylight Time

CPV Begins Operations at Stagecoach Solar in Macon County, GA

CPV

Today, Competitive Power Ventures’ (CPV) affiliate CPV Renewable Power announced the commencement of operations at CPV Stagecoach Solar, an 80-MW ac solar power generation facility in Macon County, Georgia. Utilizing over 180,000 bi-facial solar panels and single-axis tracking to maximize energy production, the project will help avoid nearly 80,000 tons of carbon dioxide emissions each year by displacing generation from older, nonrenewable facilities. This is equivalent to removing approximately 16,000 cars from the road. “Our vision for a reliable, low carbon electric supply includes a substantial amount of solar and wind which requires an accelerated build out of this technology,” said Gary Lambert, CEO of CPV. “Having the plan is only one part of the equation - actual execution takes a tremendous amount of collaboration and effort from everyone involved. We are proud to be celebrating alongside the local community and our partners as we bring emission free generation to the grid.” “Bringing our second utility-scale solar project online in just a few months shows CPV’s commitment to a lower carbon future. By working with partners and the local community, we can use our industry experience to help create a reliable, sustainable grid,” said Sean Finnerty, President of Renewables for CPV. “Of course, we would not be reaching this milestone if it were not for the support of both Andersonville and Macon County throughout the development and construction process. Our team looks forward to our continued engagement and being part of this community for many years to come.” “This was something our team worked on for a long time, bringing a solar project to this county. We are excited to see CPV Stagecoach come online and grateful to CPV for their hard work in making it a reality,” said Gerald Beckham, Executive Director of The Development Authority of Macon County and Chamber of Commerce. “Already we have reaped the economic benefits of the project, allowing us to inject funds into critical resources all while helping bring new clean energy to Georgia.” CPV Stagecoach Solar was constructed with the expertise of Vanguard Energy Partners, a leading solar Engineering, Procurement, Construction firm, which will also manage the day-to-day operations of the facility. “Safety was our highest priority during construction,” said Geoffrey Fairclough, President of Vanguard Energy Partners. “The dedication of everyone involved is evident in the high-quality result, reflecting our commitment to project excellence.” CPV Stagecoach Solar is the company’s second recent utility scale solar project to enter operations after CPV Maple Hill Solar. It joins five operating wind projects in the company’s renewable portfolio alongside nearly 4 GW of additional renewable projects in development. CPV remains committed to developing and bringing online a mix of renewable and low carbon dispatchable generation to ensure grid reliability and help drive decarbonization in a responsible way. About CPV CPV Group LP, a partnership majority owned by OPC Energy Ltd., has 25 years of unprecedented success in the development and operation of highly efficient and low emitting electric generation and renewable projects in the United States. CPV is focused on applying its development, financial and project management expertise to advance the next generation of technologies. After bringing on 5.3 GW of natural gas, wind, and solar generation since 2010 and with a current pipeline of over 10 GW of renewable and dispatchable generation projects, including utility-scale carbon capture, CPV is well positioned to help drive the nation’s decarbonization goals forward. For more information: please visit www.cpv.com and follow CPV on LinkedIn. About OPC Energy OPC Energy Ltd. (OPCE:Tel Aviv), is an energy company leading the Energy Transition revolution in Israel and the USA, and provides electricity in an efficient, reliable and environmentally friendly manner while combining solar energy, wind and natural gas with high efficiency. In Israel, OPC is the first and leading private electricity producer, offering its customers an integrated energy solution that includes the supply of all energy needs through the company's production sites and in the customer's yard using natural gas and solar energy, as well as charging electric vehicles. In the USA, the company operates through the CPV Group, which supplies electricity using efficient natural gas and wind energy, and also builds and develops Powerhouse using natural gas, natural gas with reduced emissions, as well as solar and wind energy. For more information: please visit www.opc-energy.com/en Contact Details Competitive Power Ventures Sam Loftus +1 617-347-8094 sloftus@cpv.com Company Website http://www.cpv.com

June 04, 2024 10:00 AM Eastern Daylight Time

GOLDEN TECHNOLOGIES PARTNERS WITH ROBOOTER TO INTRODUCE CUTTING-EDGE MOBILITY SOLUTIONS

Robooter

OLD FORGE, PA - June 4, 2024 - ( ThriveNewsWire ) - Golden Technologies is proud to announce its collaboration with Robooter, marking a significant milestone in the mobility industry. As the exclusive distributor of Robooter's E40 in the United States, Golden Technologies is excited to offer a diverse range of innovative products to consumers. With this partnership, Golden Technologies introduces the GP303 Golden Ally powered by Robooter, a groundbreaking folding power wheelchair designed to enhance mobility and independence for users nationwide. Rich Golden, CEO of Golden Technologies, expressed his delight at the successful collaboration between the two companies, stating, "The GP303 Ally has been exceptionally well-received, and our retailers are eager to introduce this state-of-the-art product to our customers. We are thrilled to partner with Robooter and look forward to further strengthening our relationship by introducing additional products in the near future." The Golden Ally, a result of the collaboration between Golden Technologies and Robooter, combines cutting-edge technology with ergonomic design to provide users with unparalleled comfort and functionality. Featuring a tight turning radius, luxurious memory foam seating, and ergonomically designed foot positions, the Golden Ally offers users a superior mobility experience. Additionally, users can control the wheelchair remotely via a smart mobile app, further enhancing its convenience and usability. In addition to the E40 series, Robooter's X40 and E60 series offer users a comprehensive range of mobility solutions tailored to their specific needs. With the introduction of these innovative products, Golden Technologies and Robooter reaffirm their commitment to delivering exceptional quality and innovation in the mobility industry. For more information about Robooter and Golden Technologies, please visit: Robooter: https://www.robooter.com/ Golden Technologies: https://goldentech.com/ To explore our range of products, including the X40 and E60 series, please visit: Robooter X40: https://www.robooter.com/robooter-x Robooter E60: https://www.robooter.com/robooter-e60 Contact Information Keira Zhou info@robooter.com https://www.robooter.com/ Contact Details Robooter Keira Zhou info@robooter.com Company Website https://www.robooter.com/

June 04, 2024 10:00 AM Eastern Daylight Time

Image

FIDE Announces Finalists for the 2024 World Corporate Chess Championship

Freedom US Markets

FIDE, the Fédération Internationale des Échecs (International Chess Federation), has announced the finalists in the 2024 FIDE World Corporate Chess Championship, presented by Freedom Holding Corp. As part of FIDE's centenary celebrations, this landmark event will bring together the biggest and brightest names in chess and business from June 14 to 17 at the historic Cunard Building in the heart of New York’s financial district. The championship includes eight finalists, whose strategic thinking and prowess earned them a trip to New York and seats at the chess board, as well as four wild card teams to turn up the challenge. Blending the intellectual rigor of chess with the strategic acumen of the business world, these teams will compete for international recognition and the glory of being titled the World Corporate Chess Champion. The 12 finalists competing in New York are: Nanjing Spark Chess Technology Co., Ltd. (China) ChessMood Inc. (USA) LLC “LC” “GRECO” (Ukraine) UBS Group AG (Switzerland) Chessify (USA) Tengizchevroil (Kazakhstan) Deutsche Bank (USA) SIG (USA) Wild card teams: Freedom Holding Corp. (Kazakhstan) Google (USA) Goldman Sachs (USA) BlackRock (USA) "This championship is a unique combination of chess and business – a new concept which we are looking to develop further" said FIDE President Arkady Dvorkovich. "Hosting this event in a global financial hub like New York underscores the importance of chess in advancing strategic thinking and decision-making within the corporate sector, and we want to enhance that link. We are thrilled to bring together top corporate minds worldwide and open new pathways for chess in the U.S. and globally." The 2024 World Corporate Chess Championship, presented by Freedom Holding Corp. marks a significant milestone, integrating chess into the corporate sphere for the first time. This event highlights the parallels between the chessboard and the boardroom, celebrating the strategic thinking that drives success in both arenas. The finals will take place in New York City’s Cunard Building, an opulent, historic example of New York City architecture reflecting the spirit of global maritime trade, located just a short walk from Wall Street. “We are delighted to host the inaugural event in New York City, a melting pot of diversity and an incubator of opportunity,” commented Timur Turlov, Freedom Holding Corp. Chief Executive Officer. “We have seen global citizens come together in peace and engagement over the board, and it is that spirit of fellowship and understanding amongst diverse peoples of the world that we would like the Freedom Holding Corp. name to be synonymous with this. It is an honour for us to be presenting sponsors.” Attendees will not only witness a showdown for the championship title but also have the opportunity to engage in a full weekend of thoughtful and enriching activities, such as an insightful conversation with one of the world’s strongest Grandmasters, Hikaru Nakamura, a chance to meet International Master, Levy Rozman, and an exclusive behind the scenes tour of a stock exchange. Additionally, the weekend event offers participants daily opportunities to share a drink and network with business professionals and chess enthusiasts from across the globe. Event Highlights The finals are the culmination of two online qualifying stages with entrants from around the world. The competition will feature group stage matches and intense playoff rounds, ending in the crowning of the World Corporate Chess Champion. The teams will be split into two groups, each comprising four knockout qualifiers and two invited wild-card teams. The competition will unfold in two stages: a 10-round group stage, played over two days, June 15 and 16, followed by the semi-finals with the top two teams from each group facing off, and the finals, both held on June 17. For information about tickets please visit: www.freedomcapmkts.com/chess Regulations and Participation Each team of four, plus one reserve player, may have one player with a FIDE rating exceeding 2400, and no less than three players must be employees of the company represented. This ensures a balance of professional and amateur players, making the competition both challenging and inclusive. The finals will be played at a time limit of 10 minutes plus 5 second increments per move starting from move one. Global Corporate Representation The diversity of the participating teams, representing various industries (financial, tech, energy, investment) and regions (Europe, America, Asia), showcases the global appeal and inclusivity of the World Corporate Chess Championship. This event celebrates chess and aims to enhance international corporate communication and strategic collaboration. The 2024 World Corporate Chess Championship, presented by Freedom Holding Corp. is more than a competition; it's a celebration of strategic excellence and a testament to the enduring connection between chess and business. For more information on the championship, including official regulations, live updates, and results, please visit https://worldcorporate.fide.com/. About Freedom Holding Corp. Freedom Holding Corp., a Nevada corporation, is a diversified financial services holding company conducting retail securities brokerage, securities trading, investment research, investment counseling, investment banking and underwriting services, mortgages, insurance, and commercial banking as well as several ancillary businesses which complement its core financial services businesses, all through its subsidiaries, operating under the name Freedom24 in Europe and Central Asia, and Freedom Capital Markets in the United States. Through its subsidiaries, Freedom Holding Corp. employs more than 6,000 people and is a professional participant in the Kazakhstan Stock Exchange, the Astana International Exchange, the Republican Stock Exchange of Tashkent, the Uzbek Republican Currency Exchange, and is a member of the New York Stock Exchange and the Nasdaq Stock Exchange. Freedom Holding Corp. is headquartered in Almaty, Kazakhstan, and has operations and subsidiaries in 19 countries, including Kazakhstan, the United States, Cyprus, Poland, Spain, Uzbekistan, and Azerbaijan, among others. Freedom Holding Corp.'s common shares are registered with the United States Securities and Exchange Commission and are traded under the symbol FRHC on the Nasdaq Capital Market, operated by Nasdaq, Inc. To learn more about Freedom Holding Corp., visit www.freedomholdingcorp.com. About FIDE The International Chess Federation (FIDE) is the governing body of the sport of chess, and it regulates all international chess competitions. Constituted as a non-governmental institution, it was recognized by the International Olympic Committee as a Global Sporting Organization in 1999. FIDE currently has its headquarters in Lausanne, but it was initially founded in 1924 in Paris under the motto “Gens una Sumus” (Latin for “We are one Family”). It was one of the very first International Sports Federations, alongside the governing bodies of the sports of Football, Cricket, Swimming, and Auto Racing. It is now one of the largest, encompassing 201 countries as affiliate members, in the form of National Chess Federations. Chess is nowadays a truly global sport, with dozens of millions of players in all the continents, and more than 60 million games on average played every day. Source: Freedom Holding Corp. Contact Details Freedom US Markets Al Palombo (US), Global Communications Chief +1 646-970-3419 apalombo@freedomusmkts.com Company Website https://www.freedomholdingcorp.com

June 04, 2024 09:30 AM Eastern Daylight Time

1 2 3 4 5 ... 3597